Exhibit 99.2
Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock
SAN DIEGO, May 6, 2020–Kura Oncology, Inc.(Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of $13.75 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $125.1 million. In addition, Kura has granted the underwriters a30-day option to purchase up to an additional 1,365,000 shares of common stock. The offering is expected to close on or about May 8, 2020, subject to customary closing conditions.
SVB Leerink, Cowen and Credit Suisse are acting as joint bookrunning managers in the offering. JMP Securities and H.C. Wainwright & Co. are acting asco-managers for the offering.
The securities described above are being offered by Kura pursuant to a shelf registration statement on FormS-3, including a base prospectus, that was previously filed by Kura with the Securities and Exchange Commission (the “SEC”) and that was declared effective on August 28, 2019. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at(800) 808-7525, ext. 6218, or by email atsyndicate@svbleerink.com; Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by email atPostSaleManualRequests@broadridge.com, or by phone at(833) 297-2926; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, 3rd Floor, New York, NY 10010, or by telephone at(800) 221-1037, or by email atusa.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline consists of two wholly-owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC). Kura’s pipeline is also highlighted byKO-539, a potentiallyfirst-in-class, potent and selective inhibitor of the menin-MLL protein-protein interaction currently in a Phase 1/2A clinical trial in patients with relapsed/refractory AML.
